文献速递真实世界研究与卫生经济流行病学与生物统计

巴西和南非扩大结核病预防治疗目标方案覆盖的成本与成本效果分析

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
PubMed 文献 · PLoS Med · 2022-06-13

研究基于模型模拟,评估在巴西和南非将符合世界卫生组织最低和最佳目标产品概况的结核病预防治疗方案扩大至所有符合条件的HIV感染者及家庭接触者。结果显示,最佳方案(1个月、90%完成率、100%疗效)在两国有望节约成本并减少伤残调整生命年,最低方案(3个月、70%完成率、80%疗效)亦具成本效果。

要点

  • 南非扩大最佳方案可减少38.0%的伤残调整生命年并节约成本。
  • 最佳方案在两国均具成本节约优势,最低方案具成本效果。

核心结论

  • 扩大符合最低或最佳要求的结核病预防治疗方案可能对结核病相关结局产生重要影响,并可能具有成本效果或节约成本。

研究设计与样本

  • 基于模型模拟产出,分析巴西和南非扩大结核病预防治疗方案至2023年覆盖所有符合条件的HIV感染者和家庭接触者的成本与成本效果。
  • 假设最低和最佳方案的药物成本与6个月每日异烟肼(6H)相同。
  • 最低方案持续3个月,完成率70%,疗效80%;最佳方案持续1个月,完成率90%,疗效100%。
  • 目标人群为接受抗逆转录病毒治疗的HIV感染者和已识别结核病患者的家庭接触者。
  • 现状为2019年覆盖水平下的6H方案。

主要发现

  • 巴西扩大6H和最低方案每避免一个伤残调整生命年的成本分别为7608美元和808美元,最佳方案为优势方案(节约成本并减少伤残调整生命年)。

关键数值与推荐

  • 最低方案:持续3个月,完成率70%,疗效80%。
  • 最佳方案:持续1个月,完成率90%,疗效100%。
  • 现状为6H方案在2019年覆盖水平:巴西HIV感染者30%、家庭接触者0%;南非HIV感染者69%、家庭接触者0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究仅聚焦于2个国家。
  • 未明确考虑决定开具结核病预防治疗之前产生的成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shorter, safer, and cheaper tuberculosis (TB) preventive treatment (TPT) regimens will enhance uptake and effectiveness. WHO developed target product profiles describing minimum requirements and optimal targets for key attributes of novel TPT regimens. We performed a cost-effectiveness analysis addressing the scale-up of regimens meeting these criteria in Brazil, a setting with relatively low transmission and low HIV and rifampicin-resistant TB (RR-TB) prevalence, and South Africa, a setting with higher transmission and higher HIV and RR-TB prevalence. METHODS AND FINDINGS: We used outputs from a model simulating scale-up of TPT regimens meeting minimal and optimal criteria. We assumed that drug costs for minimal and optimal regimens were identical to 6 months of daily isoniazid (6H). The minimal regimen lasted 3 months, with 70% completion and 80% efficacy; the optimal regimen lasted 1 month, with 90% completion and 100% efficacy. Target groups were people living with HIV (PLHIV) on antiretroviral treatment and household contacts (HHCs) of identified TB patients. The status quo was 6H at 2019 coverage levels for PLHIV and HHCs. We projected TB cases and deaths, TB-associated disability-adjusted life years (DALYs), and costs (in 2020 US dollars) associated with TB from a TB services perspective from 2020 to 2035, with 3% annual discounting. We estimated the expected costs and outcomes of scaling up 6H, the minimal TPT regimen, or the optimal TPT regimen to reach all eligible PLHIV and HHCs by 2023, compared to the status quo. Maintaining current 6H coverage in Brazil (0% of HHCs and 30% of PLHIV treated) would be associated with 1.1 (95% uncertainty range [UR] 1.1-1.2) million TB cases, 123,000 (115,000-132,000) deaths, and 2.5 (2.1-3.1) million DALYs and would cost $1.1 ($1.0-$1.3) billion during 2020-2035. Expanding the 6H, minimal, or optimal regimen to 100% coverage among eligible groups would reduce DALYs by 0.5% (95% UR 1.2% reduction, 0.4% increase), 2.5% (1.8%-3.0%), and 9.0% (6.5%-11.0%), respectively, with additional costs of $107 ($95-$117) million and $51 ($41-$60) million and savings of $36 ($14-$58) million, respectively. Compared to the status quo, costs per DALY averted were $7,608 and $808 for scaling up the 6H and minimal regimens, respectively, while the optimal regimen was dominant (cost savings, reduced DALYs). In South Africa, maintaining current 6H coverage (0% of HHCs and 69% of PLHIV treated) would be associated with 3.6 (95% UR 3.0-4.3) million TB cases, 843,000 (598,000-1,201,000) deaths, and 36.7 (19.5-58.0) million DALYs and would cost $2.5 ($1.8-$3.6) billion. Expanding coverage with the 6H, minimal, or optimal regimen would reduce DALYs by 6.9% (95% UR 4.3%-95%), 15.5% (11.8%-18.9%), and 38.0% (32.7%-43.0%), respectively, with additional costs of $79 (-$7, $151) million and $40 (-$52, $140) million and savings of $608 ($443-$832) million, respectively. Compared to the status quo, estimated costs per DALY averted were $31 and $7 for scaling up the 6H and minimal regimens, while the optimal regimen was dominant. Study limitations included the focus on 2 countries, and no explicit consideration of costs incurred before the decision to prescribe TPT. CONCLUSIONS: Our findings suggest that scale-up of TPT regimens meeting minimum or optimal requirements would likely have important impacts on TB-associated outcomes and would likely be cost-effective or cost saving.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Nsengiyumva NP, Campbell JR, Oxlade O, et al. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Med. 2022. PMID: 35696431. doi:10.1371/journal.pmed.1004032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。